Nektar Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 22, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	2,248	862	173	108	426	2,506
Market Cap Growth	1851.01%	398.70%	59.68%	-74.61%	-82.99%	-18.16%
Enterprise Value	1,659	681.12	0.24	-96.9	34	1,897
Last Close Price	66.61	42.28	13.95	8.48	33.90	202.65
PS Ratio	40.40	15.60	1.76	1.20	4.63	24.59
PB Ratio	2.86	9.59	2.84	0.83	1.16	3.69
P/TBV Ratio	2.26	7.94	3.15	0.82	1.15	3.64
EV/Sales Ratio	29.83	12.33	0.00	-1.08	0.37	18.62
EV/EBITDA Ratio	-	-	-	0.38	-	-
EV/EBIT Ratio	-	-	-	0.37	-	-
EV/FCF Ratio	-	-	-	0.50	-	-
Debt / Equity Ratio	0.11	0.73	1.36	0.75	0.31	0.19
Net Debt / Equity Ratio	-0.84	-1.78	-2.51	-1.42	-1.02	-0.87
Net Debt / EBITDA Ratio	3.63	1.15	1.51	0.73	1.03	1.37
Net Debt / FCF Ratio	2.38	0.77	0.86	0.96	1.21	1.38
Asset Turnover	0.11	0.19	0.28	0.16	0.10	0.08
Inventory Turnover	-	-	3.81	1.91	1.24	1.60
Quick Ratio	9.85	4.59	4.16	5.95	7.49	8.88
Current Ratio	10.21	4.97	4.26	6.45	8.00	9.34
Return on Equity (ROE)	-45.67%	-206.35%	-124.10%	-110.95%	-70.39%	-59.64%
Return on Assets (ROA)	-25.78%	-47.92%	-29.92%	-47.53%	-41.52%	-33.63%
Return on Invested Capital (ROIC)	-166.99%	-3216.03%	-302.13%	-241.19%	-160.95%	-129.35%
Return on Capital Employed (ROCE)	-28.88%	-59.70%	-35.71%	-53.31%	-44.93%	-36.34%
Buyback Yield / Dilution	-39.76%	-23.05%	-8.24%	-1.53%	-2.09%	-2.64%
Total Shareholder Return	-39.76%	-23.05%	-8.24%	-1.53%	-2.09%	-2.64%

Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q